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Background
Talimogene laherparepvec, an investigational oncolytic
immunotherapy, is a modified herpes simplex virus type-1
(HSV-1) designed to selectively replicate in tumors and to
initiate a systemic immune response to target cancer cells.
Intralesional administration of talimogene laherparepvec is
intended to result in oncolysis within injected tumors,
with lytic cell destruction promoting the local release of
progeny virus and tumor derived antigens. GM-CSF, a
product of the viral transgene, is also produced locally
such that it can recruit and stimulate antigen presenting
cells to further enhance systemic anti-tumor immune
response.
Methods
In a retrospective analysis of a Phase III melanoma trial
investigators found that about two-thirds of the lesions
injected with talimogene laherparepvec shrank 50% or
more. Among uninjected tumors similar responses were
seen in one third of lesions of the skin and lymph nodes
and about a sixth of uninjected visceral lesions providing
an indication that the treatment is triggering systemic
immune effect.
To further dissect the mechanism of action underlying
innate and adaptive immunity following viral administra-
tion, a talimogene laherparepvec expressing murine GM-
CSF (OncoVEXmGM-CSF) was employed in syngeneic
tumor models (A20 and CT26).
Results
When administered intratumorally (3 doses of 5x10^6
PFU) OncoVEXmGM-CSF induces tumor regressions in
the injected lesion, but also results in significant anti-
tumor effects in a contralateral (uninjected) lesion and
marked size increases in injected tumor draining lymph
nodes. Flow cytometric profling, gene expression analy-
sis, and IHC revealed infiltration of T cells, innate effec-
tor cells and antigen presenting cells in tumors and
draining lymph nodes. Innate immune responses in the
injected tumor are characterized by the induction of
Interferon response gene signatures and result in the
systemic release of proinflammatory cytokines. These
effects are, at least in part, dependent on STING activ-
ity, with in vitro functional assays supporting direct
agonism of this pathway by the virus. Systemic anti-
tumor responses appear to be T cell driven: T cells
expressed higher levels of activation markers as early as
2 days post-treatment in injected tumors, with evidence
of T cell activation in contralateral lesion by day 7. To
elucidate anti-viral and anti-tumor T cell responses, ex
vivo re-challenge assays were performed using spleno-
cyte- and draining lymph node-derived T cells following
treatment with OncoVEXmGM-CSF; viral treatment
increased systemic anti-tumor immunity and showed
induction of anti-viral responses.
Conclusions
In conclusion, in vitro and in vivo observations suggest
that intratumoral injection of OncoVEXmGM-CSF acti-
vates multiple immune-mediated mechanisms of action,
leading to T cell activation and induction of anti-tumor
immunity in mice.
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